204 related articles for article (PubMed ID: 18548147)
1. Reporting on sex-based analysis in clinical trials of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker efficacy.
Rabi DM; Khan N; Vallee M; Hladunewich MA; Tobe SW; Pilote L
Can J Cardiol; 2008 Jun; 24(6):491-6. PubMed ID: 18548147
[TBL] [Abstract][Full Text] [Related]
2. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
3. Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.
Zou Z; Yuan HB; Yang B; Xu F; Chen XY; Liu GJ; Shi XY
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD009210. PubMed ID: 26816003
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study.
Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315
[TBL] [Abstract][Full Text] [Related]
8. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.
Neutel JM
Curr Med Res Opin; 2010 Jan; 26(1):213-22. PubMed ID: 19921961
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
[TBL] [Abstract][Full Text] [Related]
10. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
Pirola CJ; Sookoian S
J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
[TBL] [Abstract][Full Text] [Related]
11. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
Ong HT
J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
[TBL] [Abstract][Full Text] [Related]
12. Effects of ACEIs Versus ARBs on Proteinuria or Albuminuria in Primary Hypertension: A Meta-Analysis of Randomized Trials.
Xu R; Sun S; Huo Y; Yun L; Huang S; Li G; Yan S
Medicine (Baltimore); 2015 Sep; 94(39):e1560. PubMed ID: 26426627
[TBL] [Abstract][Full Text] [Related]
13. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
[TBL] [Abstract][Full Text] [Related]
14. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
Al Khalaf MM; Thalib L; Doi SA
Am J Cardiovasc Drugs; 2009; 9(1):29-43. PubMed ID: 19178130
[TBL] [Abstract][Full Text] [Related]
17. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
18. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
19. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
Ohtsubo T; Shibata R; Kai H; Okamoto R; Kumagai E; Kawano H; Fujiwara A; Kitazono T; Murohara T; Arima H
Hypertens Res; 2019 May; 42(5):641-649. PubMed ID: 30948834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
